{"entity":{"id":"add-aspirin","kind":"trial","name":"Add-Aspirin","aka":[],"tldr":"Add-Aspirin is an 11,000-patient trial across four common cancers in the UK, Ireland and India asking whether cheap daily aspirin after curative treatment stops cancer coming back.","summary":"Add-Aspirin is a phase 3, double-blind, placebo-controlled trial with four parallel tumour-specific cohorts (breast, colorectal, gastro-oesophageal, prostate), each powered separately for disease-free or biochemical recurrence-free survival, with overall survival as a secondary endpoint. Recruitment ran from 2015 across more than 100 UK sites plus Ireland and India (Tata Memorial), reaching its target of around 11,000 participants; a feasibility analysis (Lancet Gastroenterology & Hepatology 2020) confirmed acceptable safety, including in older participants. Primary analyses are expected in the second half of the 2020s as events accrue. The trial's public funding and generic drug are the model for repurposing research that industry will not run; its PIK3CA-stratified analysis will be the first replication test for ALASCCA.","status":"active","asOf":"2026-09-08","links":[{"label":"ClinicalTrials.gov NCT02804815","url":"https://clinicaltrials.gov/study/NCT02804815"},{"label":"Add-Aspirin trial site","url":"https://www.addaspirintrial.org/"}],"tags":[],"related":[],"cancers":["colorectal","breast-hr-positive","gastric","esophageal","prostate"],"sections":["nutrition-lifestyle","prevention"],"technologies":["aspirin-cancer-prevention","drug-repurposing"],"targets":[],"drugs":["aspirin"],"companies":[],"institutions":["cruk","tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-generic-repurposing","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02804815","phase":"3","setting":"After curative treatment for breast, colorectal, gastro-oesophageal or prostate cancer: aspirin 100 mg vs 300 mg vs placebo daily for 5 years","sponsor":"University College London / Cancer Research UK / NIHR / Tata Memorial","result":"Ongoing; primary analyses pending.","started":"2015-10","enrolled":11000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/add-aspirin/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"section":[{"id":"nutrition-lifestyle","kind":"section","name":"Diet, Exercise & Lifestyle","route":"/fronts/nutrition-lifestyle/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"aspirin-cancer-prevention","kind":"technology","name":"Aspirin for cancer prevention and adjuvant therapy","route":"/technologies/aspirin-cancer-prevention/"},{"id":"drug-repurposing","kind":"technology","name":"Systematic drug repurposing","route":"/technologies/drug-repurposing/"}],"drug":[{"id":"aspirin","kind":"drug","name":"Aspirin","route":"/drugs/aspirin/"}],"institution":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/"}],"bottleneck":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-generic-repurposing","kind":"bottleneck","name":"No incentive to repurpose cheap drugs","route":"/bottlenecks/b-generic-repurposing/"}],"term":[{"id":"accrual","kind":"term","name":"Accrual and enrolment","route":"/terms/accrual/"},{"id":"double-blind","kind":"term","name":"Blinding (double-blind, open-label, placebo-controlled)","route":"/terms/double-blind/"},{"id":"informed-consent","kind":"term","name":"Informed consent","route":"/terms/informed-consent/"},{"id":"microenvironment-inflammation-theory","kind":"term","name":"Microenvironment and inflammation: tumours as wounds that do not heal","route":"/terms/microenvironment-inflammation-theory/"},{"id":"placebo","kind":"term","name":"Placebo","route":"/terms/placebo/"},{"id":"pragmatic-trial","kind":"term","name":"Pragmatic trial","route":"/terms/pragmatic-trial/"},{"id":"sample-size-re-estimation","kind":"term","name":"Statistical power, sample size and re-estimation","route":"/terms/sample-size-re-estimation/"},{"id":"trial-protocol","kind":"term","name":"Trial protocol and statistical analysis plan","route":"/terms/trial-protocol/"}],"roadmap":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/"},{"id":"trial-modernisation-roadmap","kind":"roadmap","name":"Trial modernisation roadmap: the randomised trial → platforms and adaptive designs → decentralised, pragmatic and always-on","route":"/roadmaps/trial-modernisation-roadmap/"}]}}